Trius Therapeutics (NASDAQ: TSRX) and Incyte Corporation (NASDAQ:INCY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitabiliy, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

92.8% of Incyte Corporation shares are owned by institutional investors. 13.7% of Incyte Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Trius Therapeutics and Incyte Corporation, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trius Therapeutics 0 0 0 0 N/A
Incyte Corporation 0 3 18 0 2.86

Incyte Corporation has a consensus price target of $143.33, indicating a potential upside of 5.18%. Given Incyte Corporation’s higher possible upside, analysts plainly believe Incyte Corporation is more favorable than Trius Therapeutics.

Earnings and Valuation

This table compares Trius Therapeutics and Incyte Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trius Therapeutics N/A N/A N/A N/A N/A
Incyte Corporation $1.23 billion 22.69 $35.53 million ($0.54) -252.37

Incyte Corporation has higher revenue and earnings than Trius Therapeutics.


This table compares Trius Therapeutics and Incyte Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trius Therapeutics N/A N/A N/A
Incyte Corporation -8.72% -20.09% -6.64%


Incyte Corporation beats Trius Therapeutics on 5 of the 8 factors compared between the two stocks.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings for Trius Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trius Therapeutics Inc. and related companies with's FREE daily email newsletter.